Document Detail

Increasing high-density lipoprotein as a therapeutic target in atherothrombotic disease.
MedLine Citation:
PMID:  20196993     Owner:  NLM     Status:  MEDLINE    
RESULTS: However, because statin treatment was not standardized in earlier trials, it has been difficult to draw clear
CONCLUSIONS: Recent advances in both animal studies and clinical trials indicate that increasing the HDL level could result in additional benefits to those achieved by reducing LDL levels using statins. Intravenous infusion of various HDL preparations appears to lead to the accelerated regression and stabilization of atheromatous plaque, and could provide a novel approach to treatment in high-risk patients. This review describes the biological rationale underlying the use of treatments that increase HDL and discusses the potential benefits of such treatment.
Juan José Badimón; Borja Ibáñez
Related Documents :
25069603 - Very low calorie diet without aspartame in obese subjects: improved metabolic control a...
19874273 - Early-life nutrition influences thymic growth in male mice that may be related to the r...
2104783 - Aflatoxin-dna adduct formation in chronically dosed rats fed a choline-deficient diet.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Revista española de cardiología     Volume:  63     ISSN:  1579-2242     ISO Abbreviation:  Rev Esp Cardiol     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-03-03     Completed Date:  2010-07-21     Revised Date:  2013-05-20    
Medline Journal Info:
Nlm Unique ID:  0404277     Medline TA:  Rev Esp Cardiol     Country:  Spain    
Other Details:
Languages:  eng; spa     Pagination:  323-33     Citation Subset:  IM    
Atherothrombosis Research Unit, Cardiovascular Institute, Mount Sinai Hospital, New York, NY 10029, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Atherosclerosis / blood*,  complications,  drug therapy*,  physiopathology
Lipoproteins, HDL / blood*,  metabolism
Thrombosis / blood*,  complications,  drug therapy*
Reg. No./Substance:
0/Lipoproteins, HDL

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prevalence of Patent Foramen Ovale Determined by Transesophageal Echocardiography in Patients With C...
Next Document:  The Pulmonary Circulation in Heart Failure.